eNeura Therapeutics, hard on the heels of an FDA nod for its migraine technology, brought in $2.2 million from an equity offering.
The medtech maker list a lone unnamed investor in late Dec., according to a regulatory filing.
Sunnyvale, Calif.-based eNeura won FDA clearance for its Cerena transcranial magnetic stimulator, through the agency’s less-stringent de novo premarket review pathway in Dec.
The Cerena TMS device is designed to use magnetic energy to help relieve pain associated with migraines, stimulating the occipital cortex in the brain via a prescription device that patients hold against the back of the head after the onset of pain.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.